Vancouver's AbCellera Biologics Sets Terms for Monster IPO, Could Value the Company at Up to US $4.5 Billion (and Raise as Much as $391M US)

Tuesday, December 8, 2020

Website

Vancouver, BC, December 8, 2020--AbCellera Biologics said that terms of its initial public offering have been set, which could value the artificial intelligence (AI)-powered drug discovery company at up to $4.52 billion. The Vancouver-based company, which is working with Eli Lilly & Co. on a COVID-19 therapy, said it is offering 23 million shares in the IPO, which is expected to price between $14 and $17 a share, which means the company could raise as much as $391 million and value the Compa